share_log

ProQR Therapeutics Analyst Ratings

Benzinga ·  Sep 18, 2023 21:39
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/18/2023 11.8% Citigroup $2.1 → $1.8 Maintains Buy
08/07/2023 210.56% HC Wainwright & Co. → $5 Reiterates Buy → Buy
08/04/2023 24.22% Chardan Capital → $2 Reiterates Neutral → Neutral
05/17/2023 179.5% Cantor Fitzgerald $5 → $4.5 Maintains Overweight
05/17/2023 272.67% JMP Securities → $6 Reiterates Market Outperform → Market Outperform
05/17/2023 210.56% HC Wainwright & Co. → $5 Reiterates Buy → Buy
03/30/2023 272.67% JMP Securities → $6 Reiterates → Market Outperform
03/30/2023 210.56% HC Wainwright & Co. $1.5 → $5 Maintains Buy
12/23/2022 210.56% Raymond James $2 → $5 Maintains Outperform
12/22/2022 210.56% Cantor Fitzgerald $0.8 → $5 Upgrades Neutral → Overweight
08/15/2022 -6.83% HC Wainwright & Co. $2 → $1.5 Maintains Buy
08/12/2022 Chardan Capital Downgrades Buy → Neutral
08/12/2022 24.22% Raymond James → $2 Upgrades Market Perform → Outperform
05/09/2022 24.22% HC Wainwright & Co. $4 → $2 Maintains Buy
05/06/2022 24.22% Chardan Capital $2.5 → $2 Maintains Buy
04/14/2022 55.28% Chardan Capital $8 → $2.5 Maintains Buy
04/14/2022 210.56% JMP Securities $8 → $5 Maintains Market Outperform
02/14/2022 396.89% Chardan Capital $18 → $8 Maintains Buy
02/14/2022 396.89% JMP Securities $29 → $8 Maintains Market Outperform
02/14/2022 148.45% HC Wainwright & Co. $20 → $4 Maintains Buy
02/14/2022 Raymond James Downgrades Strong Buy → Market Perform
02/01/2022 1080.12% Raymond James → $19 Initiates Coverage On → Strong Buy
08/09/2021 1018.01% Chardan Capital $20 → $18 Maintains Buy
05/03/2021 1142.24% Stifel → $20 Initiates Coverage On → Buy
08/11/2020 1142.24% Chardan Capital $25 → $20 Maintains Buy
11/19/2019 1949.69% Citigroup $40 → $33 Maintains Buy
11/14/2018 2384.47% Cantor Fitzgerald → $40 Initiates Coverage On → Overweight
09/19/2018 2073.91% Evercore ISI Group → $35 Initiates Coverage On → Outperform

What is the target price for ProQR Therapeutics (PRQR)?

The latest price target for ProQR Therapeutics (NASDAQ: PRQR) was reported by Citigroup on September 18, 2023. The analyst firm set a price target for $1.80 expecting PRQR to rise to within 12 months (a possible 11.80% upside). 10 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for ProQR Therapeutics (PRQR)?

The latest analyst rating for ProQR Therapeutics (NASDAQ: PRQR) was provided by Citigroup, and ProQR Therapeutics maintained their buy rating.

When is the next analyst rating going to be posted or updated for ProQR Therapeutics (PRQR)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProQR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProQR Therapeutics was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.

Is the Analyst Rating ProQR Therapeutics (PRQR) correct?

While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a maintained with a price target of $2.10 to $1.80. The current price ProQR Therapeutics (PRQR) is trading at is $1.61, which is out of the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment